Biofrontera Posts $9.1M Q3 Revenue but Swings to $6.4M Net Loss
BFRI sits 47% above its 52-week low of $0.555 on light trading volume (0.3× avg).
Summary
Biofrontera reported Q3 revenue of $9.1 million, up 30% on higher Ameluz sales, alongside a $6.4 million net loss, or $0.42 per share, and negative adjusted EBITDA of $5.5 million. The loss lands against a going-concern warning disclosed in the last 10-Q, so the cash burn is the number that matters here, not the top line. This is the first quarterly report since the September 8-K disclosing FDA approval of Ameluz for superficial basal cell carcinoma, and the October supplemental NDA filing to expand the red-light photodynamic therapy label — neither has yet shown up in revenue. With the stock at $0.81 and a micro-cap valuation, the company's ability to fund the launch without fresh capital is the open question. No specific date for the next filing or financing update was provided.
At the time of this announcement, BFRI was trading at $0.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.8M. The 52-week trading range was $0.55 to $1.66. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.